A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier

Cancer Prevention Research

Volumn 8, Issue 1, 2015, Pages 68-76

  Adkins, Chris E ^a,b   Nounou, Mohamed I ^b,c   Mittapalli, Rajendar K ^b   Terrell Hall, Tori B ^a,b   Mohammad, Afroz S ^a,b   Jagannathan, Rajaganapathi ^a   Lockman, Paul R ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

GALUNISERTIB; TRANSFORMING GROWTH FACTOR BETA; LY-2157299; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER PREVENTION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR EXTRAVASATION; TUMOR SEEDING; ANIMAL; BRAIN; BRAIN TUMOR; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; FLUORESCENCE MICROSCOPY; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; PYRAZOLES; QUINOLINES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84920771223     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0225     Document Type: Article

References (55)

1. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 2013;309:800-5.
2. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14.
3. Shaffrey ME, Mut M, Asher AL, Burri SH, Chahlavi A, Chang SM, et al. Brain metastases. Curr Probl Surg 2004;41:665-741.
4. Engel J, Eckel R, Aydemir U, Aydemir S, Kerr J, Schlesinger-Raab A, et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003;55:1186-95.
5. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17.
6. Bent vd. The role of chemotherapy in brain metastases. Eur J Cancer 2003;39:2114-20.
7. Lin N, Carey L, Liu M, Younger J, Come S, Ewend M, et al. Phase II trial of lapatinib for brain metasetases in patients with human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2008;26:1993-9.
8. Ekenel M, Hormigo A, Peak S, DeAngelis L, Abrey L. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007;85:223-7.
9. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases of breast cancer. Cancer 2006;107:1348-54.
10. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
11. Genka S, Deutsch J, Shetty UH, Stahle PL, John V, Lieberburg IM, et al. Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil. Clin Exp Metastasis 1993;11:131-40.
12. Lesser GJ, Grossman SA, Eller S, Rowinsky EK. The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother Pharmacol 1995;37:173-8.
13. Rowinsky EK. On pushing the outer edge of the outer edge of paclitaxel's dosing envelope. Clin Cancer Res 1999;5:481-6.
14. Zimmermann M, Box C, Eccles SA. Two-dimensional vs. three-dimensional in vitro tumor migration and invasion assays. Methods Mol Biol 2013;986:227-52.
15. Coisne C, Lyck R, Engelhardt B. Live cell imaging techniques to study T cell trafficking across the blood-brain barrier in vitro and in vivo. Fluids Barriers CNS 2013;10:7.
16. Lippmann ES, Al-Ahmad A, Palecek SP, Shusta EV. Modeling the bloodbrain barrier using stem cell sources. Fluids Barriers CNS 2013;10:2.
17. Zhang C, Zhang F, Tsan R, Fidler IJ. Transforming growth factor-beta2 is a molecular determinant for site-speci fic melanoma metastasis in the brain. Cancer Res 2009;69:828-35.
18. Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM, MacKenzie LT, et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med 2006;56:1001-10.
19. Marsden CG, Wright MJ, Carrier L, Moroz K, Pochampally R, Rowan BG. A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies. BMC Cancer 2012;12:10.
20. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS. The biology of metastasis to a sanctuary site. Clin Cancer Res 2007;13:1656-62.
21. Yoneda T, Williams P, Hiraga T, Niewolna M, Nishimura R. A bone seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone and Mineral Res 2001;16:1486-95.
22. Kappes JC, Wu X. Safety considerations in vector development. Magn Reson Med 2001;26:147-58.
23. Kappes JC, Wu X, Wake field JK. Production of trans-lentiviral vector with predictable safety. Methods Mol Med 2003;76:449-65.
24. Cheng X, Hung MC. Breast cancer brain metastases. Cancer Metastasis Rev 2007;26:635-43.
25. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011;11:352-63.
26. Motl S, Zhuang Y, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumors. Clin Pharmacokinet 2006;45:871-903.
27. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010;16:5664-78.
28. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69:972-80.
29. Freilich RJ, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995;76:232-6.
30. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53:259-65.
31. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, et al. Her-2 overexpression increases themetastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007;67:4190-8.
32. Song HT, Jordan EK, Lewis BK, Liu W, Ganjei J, Klaunberg B, et al. Ratmodel of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J Transl Med 2009;7:88.
33. Fitzgerald D, Palmieri D, Hua E, Hargrave E, Herring J, Qian Y, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metast 2008;25:799-810.
34. Biggers B, Knox S, Grant M, Kuhn J, Nemunatitis J, Fisher T, et al. Circulating tumor cells in patients undergoing surgery for primary breast cancer: preliminary results of a pilot study. Ann Surg Oncol 2009;16:969-71.
35. Sandri MT, Zorzino L, Cassatella MC, Bassi F, Luini A, Casadio C, et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol 2010;17:1539-45.
36. Krag DN, Ashikaga T, Moss TJ, Kusminsky RE, Feldman S, Carp NZ, et al. Breast cancer cells in the blood: a pilot study. Breast J 1999;5:354-8.
37. Banys M, Krawczyk N, Becker S, Jakubowska J, Staebler A, Wallwiener D, et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat 2012;132:121-9.
38. Demicheli R, Valagussa P, Bonadonna G. Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer 2001;85:490-2.
39. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-8.
40. Hayashi K, Jiang P, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, et al. Real-time imaging of tumor-cell shedding and trafficking in lymphatic channels. Cancer Res 2007;67:8223-8.
41. Glaves D. Correlation between circulating cancer cells and incidence of metastases. Br J Cancer 1983;48:665-73.
42. Swartz MA, Kristensen CA, Melder RJ, Roberge S, Calautti E, Fukumura D, et al. Cells shed from tumors show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity. Br J Cancer 1999;81:756-9.
43. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
44. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 1975;35:512-6.
45. Zhao S, Liu Y, Zhang Q, Li H, Zhang M, Ma W, et al. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature. Breast Cancer Res Treat 2011;130:809-16.
46. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a European pooled analysis. Clin Cancer Res 2011;17:2967-76.
47. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
48. Liu Z, Kobayashi K, van Dinther M, van Heiningen SH, Valdimarsdottir G, van Laar T, et al. VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression. J Cell Sci 2009;122:3294-302.
49. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, et al. Semimechanistic modeling of the tumor growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 2008;44:142-50.
50. Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995;14:279-301.
51. Lyck R, Engelhardt B. Going against the tide-how encephalitogenic T cells breach the blood-brain barrier. J Vasc Res 2012;49:497-509.
52. Cucullo L, Marchi N, Hossain M, Janigro D. A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system. J Cereb Blood Flow Metab 2011;31:767-77.
53. Reijerkerk A, Lakeman KA, Drexhage JA, van Het Hof B, van Wijck Y, van der Pol SM, et al. Brain endothelial barrier passage by monocytes is controlled by the endothelin system. J Neurochem 2012;121:730-7.
54. Strell C, Entschladen F. Extravasation of leukocytes in comparison to tumor cells. Cell Commun Signaling 2008;6:10.
55. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010;16:116-22.